CCR2 and hepatocellular carcinoma: In murine models of hepatocellular carcinoma, combined treatment with the CCR2 antagonists, RDC018 or 747, with sorafenib was validated to inhibit tumor growth and metastasis, accompanied by a significant reduction of macrophage infiltration.321, 322